|
Improving outcomes with brentuximab vedotin (BV) plus chemotherapy in patients with newly diagnosed advanced stage Hodgkin lymphoma. |
|
|
Consulting or Advisory Role - Bayer; Seagen |
Research Funding - Takeda |
|
|
Honoraria - Bristol-Myers Squibb; Celleron Therapeutics; Gilead Sciences; MSD; Pfizer; Roche; Takeda |
Consulting or Advisory Role - Bristol-Myers Squibb; Celleron Therapeutics; Gilead Sciences; MSD; Pfizer; Roche; Takeda |
Speakers' Bureau - Roche; Takeda |
Research Funding - Amgen; Celgene; Celleron Therapeutics; MSD |
Travel, Accommodations, Expenses - Roche; Takeda |
|
|
Honoraria - Celgene; Janssen-Cilag; Roche; Servier; Takeda |
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; Incyte; Janssen-Cilag; Roche |
Research Funding - GlaxoSmithKline/Novartis (Inst); Janssen-Cilag (Inst); Roche (Inst); Takeda (Inst) |
Travel, Accommodations, Expenses - Gilead Sciences; Roche |
|
|
No Relationships to Disclose |
|
|
Honoraria - Bristol-Myers Squibb; Gilead Sciences; Merck; Roche; Takeda |
Consulting or Advisory Role - Bristol-Myers Squibb; Gilead Sciences; Merck; Roche; Takeda |
Research Funding - Seagen; Takeda |
Travel, Accommodations, Expenses - Amgen |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Celgene; Janssen; Novartis; Roche; Takeda |
Research Funding - Seagen (Inst); Takeda (Inst) |
Travel, Accommodations, Expenses - Roche; Takeda |
|
|
No Relationships to Disclose |
|
|
Research Funding - Seagen; Takeda |
|
|
|
Consulting or Advisory Role - Takeda |
Research Funding - Seagen; Takeda; Varian Medical Systems |
Travel, Accommodations, Expenses - Merck Serono; Takeda |
|
|
Research Funding - Seagen (Inst); Takeda (Inst) |
|
|
Honoraria - Abbvie; Bristol-Myers Squibb; Gilead Sciences; Janssen; Merck; Roche; Takeda |
Consulting or Advisory Role - Asana Biosciences; Bayer; Bristol-Myers Squibb; Genentech/Roche; Gilead Sciences; Incyte; Janssen; Merck; Seagen; Takeda |
Research Funding - Bristol-Myers Squibb (Inst); Curis (Inst); Janssen (Inst); Novartis (Inst); Roche/Genentech (Inst) |
|
|
Research Funding - Amgen (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Cephalon (Inst); Genentech/Roche (Inst); Janssen Oncology (Inst); Lilly (Inst); Merck (Inst); NanoString Technologies (Inst); Roche (Inst); Seagen (Inst); Takeda (Inst) |
Patents, Royalties, Other Intellectual Property - Evaluation of mantle cell lymphoma and methods related thereof (Inst); Methods for selecting and treating lymphoma types (Inst) |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Takeda |
|
|
|
Stock and Other Ownership Interests - Seagen |
|
|
|
Stock and Other Ownership Interests - Seagen |
|
|
|